Methoxybenzoic acids and derivatives
Medchemexpress LLC OGG1-IN-08 | 350997-39-6 | 99.18% | 261.13 | 1 ML
OGG1-IN-08 is a potent 8-oxoguanine DNA glycosylase-1 (OGG1) inhibitor with an IC50 value of 0.22 μM. It decreases both the glycosylase and lyase activities of OGG1. The product is for research use only and not sold to patients.
- Potent 8-oxoguanine DNA glycosylase-1 (OGG1) inhibitor
- IC50 value of 0.22 μM against OGG1
- Decreases both the glycosylase and lyase activities of OGG1
- Inhibits different DNA glycosylases activities: NEIL1 (84.56%), NTH1 (63.09%), and Fpg (91.74%) at 50 μM
- Inhibitory OGG1 lyase activity on a substrate containing an AP site at 10 μM
- Decreases the number of bases released by OGG1 for both 8-oxo-Gua and FapyGua at 10 μM
Medchemexpress LLC ESI-08 | 301177-43-5 | 98.7% | 353.48 | 1 ML
ESI-08 is a potent and selective EPAC antagonist. It completely inhibits both EPAC1 and EPAC2 activity, selectively blocking cAMP-induced EPAC activation without inhibiting cAMP-mediated PKA activation. Exchange proteins directly activated by cAMP (EPAC) are guanine nucleotide exchange factors regulating intracellular processes in response to the second messenger cAMP.
- Potent and selective EPAC antagonist
- Completely inhibits EPAC1 and EPAC2 activity
- Selectively blocks cAMP-induced EPAC activation
- Does not inhibit cAMP-mediated PKA activation
Apexbio Technology LLC Ro 08-2750 37854-59-4 1mg
Ro 08-2750 (CAS 37854-59-4) is a small molecule antagonist of nerve growth factor (NGF) that selectively inhibits NGF binding to the p75 neurotrophin receptor (p75NTR) over TrkA With an IC50 of 1 M for NGF binding Ro 08-2750 induces a conformational change in NGF preventing its interaction with p75NTR while sparing TrkA association at lower concentrations In vitro studies demonstrate that Ro 08-2750 modulates NGF-mediated signaling including suppression of NGF-induced apoptosis in SK-N-MC cells and enhancement of TrkA pathway activity in PC12 cells This compound serves as a valuable tool for investigating the distinct roles of p75NTR and TrkA in neuronal apoptosis differentiation and axonal growth
Medchemexpress LLC Ro 08-2750 | 37854-59-4 | 98.01% | 270.24 | 10 MG
Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor that binds to NGF with an IC50 of approximately 1 μM. It selectively inhibits NGF binding to p75NTR over TRKA. Ro 08-2750 is also a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM.
- Binds to the NGF dimer, potentially inducing a conformational change that prevents NGF from binding to p75NTR.
- Completely rescues cells from NGF-induced SK-N-MC 103 cell death at 10 nM.
- Increases differentiation and apoptosis in myeloid leukemia cells at 5-10 μM (8 hours).
- Inhibits survival of human AML lines and patient cells.
- Inhibits MSI2 RNA-binding and alters MSI2 gene signature.
- Inhibits leukemogenesis in a myeloid leukemia model in vivo at 13.75 mg/kg (i.p.).
- Reduces c-MYC levels and disease burden in a myeloid leukemia model.